DNDN's advantage over AGEN is at the leukapheresis vs. tumour resection stage. The latter can obviously be problematic. If that step goes swimmingly, then AGEN's technology becomes easier to produce / replicate.
But since both require that you re-introduce a biological that has been processed ex vivo back into the patient, both have equal QC hurdles, in my opinion. Perhaps DNDN has just a slightly higher hurdle at reinjection time since they're reinjecting relatively larger volume compared to AGEN and have to pay closer attention to pH / salinity; but it's far from an insurmountable task.
In my opinion, CEGE's GVAX is the easiest to prepare and ensure QC.
Market Data 
Markets 
AI
